Author: Customer Service

Inside InformationPhase 3 trial with ACARIZAX® in Chinese participants met the primary objective and showed efficacy in line with previous trials, after only 24-28 weeks of treatment. ACARIZAX® was shown to be safe and well-tolerated, consistent with data obtained in previous trials over the past 10+ years. ALK will now work with its partner GenSci to file for regulatory approval of ACARIZAX® in China. Filing is expected in first half of 2027.ALK (ALKB:DC / Nasdaq Copenhagen: ALK B) today announced positive topline results from the phase 3 bridging trial evaluating the efficacy and safety of its house dust mite (‘HDM’) sublingual immunotherapy (‘SLIT’) tablet, ACARIZAX®, in Chinese participants aged 12 – 65 years with HDM allergic rhinitis/rhinoconjunctivitis, with or without asthma. The trial was designed to show a consistent...

Facility gives the Company discretion to access equity capital over time to support its Florida dental laboratory strategy ORLANDO, Fla., Oct. 19, 2026 (GLOBE NEWSWIRE) — Standard Dental Labs Inc. (OTCQB: TUTH) (“SDL” or the “Company”), after several weeks of negotiation, today announced that it finalized its common stock purchase agreement with Twenty Four Capital LLC over the weekend. The agreement provides for the potential sale of up to $10 million of SDL common stock, subject to its terms and conditions. The facility is designed to give SDL discretion over when to request purchases and how much capital to seek, within the agreement’s limits. Twenty Four Capital is obligated to purchase shares under a qualifying purchase notice, subject to the applicable conditions. SDL is not required to sell any shares. The $10 million figure...

Utilities in Sweden, Norway and Finland are using grid intelligence across operations as load growth, customer expectations and DER growth add pressure87% of Nordic utilities say their most significant data and intelligence investments have enabled at least two additional use cases beyond their original purpose, including 47% that report four or more. Load growth is the region’s top grid stressor at 47%, followed by customer expectations and DER growth at 38% each. Lack of automation is the leading barrier to using data for decision-making, cited by 60% of Nordic utilities. Over the next three years, Nordic utilities are prioritising cloud analytics (24%), executive decision support (22%) and enterprise integration (21%).LIBERTY LAKE, Wash., Oct. 19, 2026 (GLOBE NEWSWIRE) — Itron, Inc. (NASDAQ: ITRI), the intelligent infrastructure...

Utilities are turning grid intelligence into action to address growing load, customer and infrastructure pressures93% of utilities say significant data and intelligence investments have enabled at least two additional use cases beyond their original purpose, including 47% that report four or more. Load growth is utilities’ top grid stressor at 43%, followed by rising customer expectations at 36%. Over the next three years, utilities are prioritizing enterprise integration (28%), executive decision support (23%) and workflow automation (20%).LIBERTY LAKE, Wash., Oct. 19, 2026 (GLOBE NEWSWIRE) — Itron, Inc. (NASDAQ: ITRI), the intelligent infrastructure provider for modern energy and water management, today released its 2026 Resourcefulness Report: Data Analytics and the Intelligent Grid—How Do Utilities Turn Intelligence into...

ATHENS, Greece, Oct. 19, 2026 (GLOBE NEWSWIRE) — Imperial Petroleum Inc. (Nasdaq: IMPP) (the “Company”), a ship-owning company providing petroleum products, crude oil, and drybulk seaborne transportation services, announced today that the Company’s management estimates Imperial Petroleum Inc’s Net Asset Value (“NAV”) to be $691.1 million. This translates to a NAV of $14.93 per common share currently outstanding and $11.72 per common share on a fully diluted basis (assuming exercise of outstanding warrants and options for cash), The Company also announced that it has recently taken delivery of three additional vessels, for which it had previously announced acquisition agreements. The drybulk carrier Eco Cathar (2012 built) and the product tanker Clean Raider (2010 built) were delivered to the Company in late September 2026. The drybulk...

Purpose-built for direct-to-device connectivity, C-3 satellites are expected to launch beginning next year COVINGTON, La., Oct. 19, 2026 (GLOBE NEWSWIRE) — Globalstar, Inc. (NASDAQ: GSAT), a next-generation telecommunications infrastructure and technology provider, today announced that the United States Federal Communications Commission (“FCC”) issued an order granting Globalstar nationwide authority to operate its previously announced third-generation C-3 MSS System. This authorization is the result of the continued cooperation between Globalstar and the FCC that now spans more than three decades. With this authorization, Globalstar’s C-3 satellites will be able to communicate with hundreds of millions of mobile earth terminals located in the United States, including direct-to-device (“D2D”) connectivity to smartphones. This authorization...

SUNNYVALE, Calif., Oct. 19, 2026 (GLOBE NEWSWIRE) — BioCardia, Inc. [NASDAQ: BCDA], a global leader in cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today announced the FDA has accepted its pre-submission package for marketing clearance of its Helix catheter (“Helix”) intended for therapeutic and diagnostic agent delivery. In May 2026, the Company and FDA met and reviewed our initial De Novo pre-submission package. FDA agreed that there are two pathways for Helix marketing clearance and raised no concerns regarding the product’s safety data, performance, or compatibility with general classes of agents. In August 2026, FDA confirmed and accepted the meeting minutes. In September 2026, the De Novo pre-submission was revised, incorporating the advice from FDA CDRH as detailed in...

Investigator-sponsored study funded by the French National Cancer Institute (INCa) meets pre-specified primary efficacy success criterion with 61.3% 12-month overall survival. Exploratory Subgroup analysis reveals significant survival benefit in right-sided tumors. AUSTIN, Texas, Oct. 19, 2026 (GLOBE NEWSWIRE) — XBiotech Inc. (NASDAQ: XBIT) today announced positive final efficacy results from the randomized Phase II portion of the multicenter TASKIN clinical trial. The investigator-sponsored study—funded by the French National Cancer Institute (INCa) and coordinated by investigators at the Centre Georges-François Leclerc (CGFL) in Dijon, France—evaluated the addition of XBiotech’s anti-IL-1α monoclonal antibody, XB2001 (Natrunix™, vilamakitug), to standard-of-care trifluridine/tipiracil (TAS-102) with or without bevacizumab...